Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin
- PMID: 32582272
- PMCID: PMC7295948
- DOI: 10.3389/fgene.2020.00426
Chemotherapy Curability in Leukemia, Lymphoma, Germ Cell Tumors and Gestational Malignancies: A Reflection of the Unique Physiology of Their Cells of Origin
Abstract
Cytotoxic DNA damaging chemotherapy brings clinical benefits in the treatment of many metastatic malignancies. However routine curative treatment remains restricted to a small number of malignancies including acute leukemia, high grade lymphoma, germ cell tumors, gestational malignancies and some of the rare childhood cancers. The detailed explanation for this dramatic divergence in outcomes remains to be elucidated. However, we have previously argued that there is a strong correlation between presence of the unique genetic events of immunoglobulin gene variable/diversity/joining (VDJ) recombination, somatic hypermutation (SHM), meiosis, nuclear fusion and gastrulation occurring in cells of origin of these malignancies and their high sensitivity to DNA damaging chemotherapy. In this study we have reviewed some of the basic physiological information relating to the specialized activity and sensitivity to DNA damage mediated apoptosis of normal cells undergoing these processes. In each of unique genetic events there are dramatic changes in apoptotic sensitivity. In VDJ recombination and somatic hypermutation over 95% of the cells involved undergo apoptosis, whilst in meiosis and nuclear fusion there are dramatic short term increases in the apoptotic sensitivity to DNA damage. It is apparent that each of the malignancies arising during these processes retains some of the unique phenotype associated with it. The impact of the physiological differences is most clearly seen in the two non-mutational malignancies. Gestational choriocarcinoma which arises shortly after nuclear fusion is routinely curable with chemotherapy whilst CIMP-positive ependymomas which is not linked to any of the unique genetic events is highly resistant. A similar pattern is found in a pair of malignancies driven by a single driver mutation. Infantile acute lymphoblastic leukemia (ALL) arises in a cell undergoing the early stages of VDJ recombination and has a 40% cure rate in contrast pediatric rhabdoid malignancy which is not linked to a unique genetic event responds very poorly to chemotherapy treatment. The physiological changes occurring in cancer cells at the time of the malignant transformation appear to have a major impact on the subsequent sensitivity to chemotherapy and curability. New therapies that impact on these pathways may be of therapeutic value.
Keywords: apoptosis; cancer; chemotherapy; cure; phenotype.
Copyright © 2020 Savage.
Figures



Similar articles
-
Chemotherapy curable malignancies and cancer stem cells: a biological review and hypothesis.BMC Cancer. 2016 Nov 21;16(1):906. doi: 10.1186/s12885-016-2956-z. BMC Cancer. 2016. PMID: 27871274 Free PMC article. Review.
-
Clinical observations on chemotherapy curable malignancies: unique genetic events, frozen development and enduring apoptotic potential.BMC Cancer. 2015 Jan 21;15:11. doi: 10.1186/s12885-015-1006-6. BMC Cancer. 2015. PMID: 25605631 Free PMC article.
-
Why does cytotoxic chemotherapy cure only some cancers?Nat Clin Pract Oncol. 2009 Jan;6(1):43-52. doi: 10.1038/ncponc1260. Epub 2008 Nov 4. Nat Clin Pract Oncol. 2009. PMID: 18982000 Review.
-
Germ cell tumors of the gonads: a selective review emphasizing problems in differential diagnosis, newly appreciated, and controversial issues.Mod Pathol. 2005 Feb;18 Suppl 2:S61-79. doi: 10.1038/modpathol.3800310. Mod Pathol. 2005. PMID: 15761467 Review.
-
What do somatic hypermutation and class switch recombination teach us about chronic lymphocytic leukaemia pathogenesis?Curr Top Microbiol Immunol. 2005;294:71-89. doi: 10.1007/3-540-29933-5_5. Curr Top Microbiol Immunol. 2005. PMID: 16323428 Review.
Cited by
-
Evolutionary determinants of curability in cancer.Nat Ecol Evol. 2023 Nov;7(11):1761-1770. doi: 10.1038/s41559-023-02159-w. Epub 2023 Aug 24. Nat Ecol Evol. 2023. PMID: 37620552 Review.
-
Synergistic Enhancement of Chemotherapy-Induced Cell Death and Antitumor Efficacy against Tumoral T-Cell Lymphoblasts by IMMUNEPOTENT CRP.Int J Mol Sci. 2024 Jul 20;25(14):7938. doi: 10.3390/ijms25147938. Int J Mol Sci. 2024. PMID: 39063180 Free PMC article.
References
-
- Adam P., Schoof J., Hartmann M., Schwarz S., Puppe B., Ott M., et al. (2007). Cell migration patterns and ongoing somatic mutations in the progression of follicular lymphoma. Cytogenet. Genome Res. 118 328–336. - PubMed
-
- Agraz-Doblas A., Bueno C., Bashford-Rogers R., Roy A., Schneider P., Bardini M., et al. (2019). Unraveling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis. Haematologica 104 1176–1188. 10.3324/haematol.2018.206375 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources